Q4 2023 · 13F-HR
Cormorant Asset Management, LPholdings as filed
Filed 2024-02-14 · accession 0001583977-24-000001
$2.09B
Reported value
48
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $513.0M | 24.5% | 8,494,151 | Common | SOLE |
| 641871108 | — | AMBRX BIOPHARMA INC | $159.9M | 7.64% | 11,231,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $139.5M | 6.66% | 6,038,235 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $135.0M | 6.45% | 3,344,179 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $94.3M | 4.51% | 1,700,000 | Common | SOLE |
| 75525N107 | — | RAYZEBIO INC | $75.4M | 3.60% | 1,213,478 | Common | SOLE |
| 09077A106 | BMEA | BIOMEA FUSION INC | $51.8M | 2.48% | 3,570,872 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $49.1M | 2.34% | 1,165,000 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $48.6M | 2.32% | 2,550,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $48.0M | 2.29% | 1,711,460 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HLDGS INC | $46.8M | 2.23% | 3,142,079 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $45.0M | 2.15% | 2,221,422 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $42.5M | 2.03% | 1,800,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $41.8M | 1.99% | 665,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $40.9M | 1.95% | 1,150,000 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $37.4M | 1.79% | 625,000 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $35.3M | 1.69% | 3,250,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $35.1M | 1.68% | 5,450,000 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $34.5M | 1.65% | 2,456,800 | Common | SOLE |
| 45254E107 | IMRX | IMMUNEERING CORP | $30.9M | 1.48% | 4,204,364 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $27.9M | 1.33% | 2,551,989 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $27.4M | 1.31% | 1,211,696 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $27.4M | 1.31% | 1,182,563 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $25.4M | 1.21% | 1,175,000 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $25.4M | 1.21% | 529,170 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $25.3M | 1.21% | 550,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $22.8M | 1.09% | 2,130,000 | Common | SOLE |
| 41358P205 | HARPUSD | HARPOON THERAPEUTICS INC | $22.6M | 1.08% | 2,349,060 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $20.2M | 0.96% | 937,080 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $17.8M | 0.85% | 575,000 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $16.0M | 0.76% | 450,000 | Common | SOLE |
| 05465P101 | AXNX* | AXONICS INC | $15.6M | 0.74% | 250,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $14.5M | 0.69% | 746,180 | Common | SOLE |
| 54300N103 | — | LONGBOARD PHARMACEUTICALS IN | $14.2M | 0.68% | 2,353,141 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $14.1M | 0.67% | 633,345 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $13.5M | 0.64% | 450,000 | Common | SOLE |
| 75382E109 | — | RAPT THERAPEUTICS INC | $12.3M | 0.59% | 496,750 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $7.2M | 0.34% | 125,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $5.7M | 0.27% | 1,087,807 | Common | SOLE |
| 28106W103 | EDIT | EDITAS MEDICINE INC | $5.1M | 0.24% | 500,000 | PUT | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $4.9M | 0.23% | 350,000 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $4.7M | 0.22% | 75,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $4.5M | 0.21% | 561,600 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $3.5M | 0.17% | 81,963 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $3.4M | 0.16% | 593,043 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC | $3.2M | 0.16% | 1,394,336 | Common | SOLE |
| 09077B104 | BCABGBP | BIOATLA INC | $2.9M | 0.14% | 1,181,115 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $1.6M | 0.08% | 92,293 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.